Avidity Biosciences (NASDAQ: RNA) announced encouraging initial data from the phase I/II FORTITUDE study evaluating two doses of delpacibart braxlosiran (del-brax, or formerly AOC 1020) in facioscapulohumeral muscular dystrophy (FSHD), a rare genetic disease of the muscles.
Frazier Life Sciences Management L.P. grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,764,232 shares of the company’s stock after buying an additional 80,000 shares during […]
Frazier Life Sciences Management L.P. grew its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Free Report) by 0.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 8,764,232 shares of the company’s stock after buying an additional 80,000 shares during […]
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of Arcutis Biotherapeutics stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.75, for a total transaction of $201,250.00. Following the completion of the sale, the insider now owns 209,793 shares of the […]
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT – Get Free Report) insider Patrick Burnett sold 23,000 shares of the stock in a transaction that occurred on Thursday, May 30th. The stock was sold at an average price of $8.75, for a total value of $201,250.00. Following the sale, the insider now directly owns 209,793 shares of the company’s […]